Leerink Partnrs Has Strong Estimate for MOLN Q3 Earnings

Key Points

• Leerink Partners has raised its earnings per share (EPS) estimate for Molecular Partners for Q3 2025 from ($0.53) to ($0.46), indicating improved expectations for the company’s performance.
• Molecular Partners reported a loss of $0.67 EPS in its latest earnings, missing the consensus estimate of ($0.53) by $0.14.
• Institutional investor BVF Inc. IL increased its stake in Molecular Partners by 205.5%, acquiring an additional 910,747 shares, highlighting significant investor confidence in the company.

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) - Stock analysts at Leerink Partnrs increased their Q3 2025 earnings per share estimates for Molecular Partners in a research report issued on Monday, August 25th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their previous forecast of ($0.53). The consensus estimate for Molecular Partners' current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners' Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.04) EPS and FY2026 earnings at ($1.60) EPS.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its quarterly earnings data on Monday, August 25th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.14).

Molecular Partners Trading Up 6.3%

NASDAQ MOLN traded up $0.23 on Thursday, reaching $3.83. The company's stock had a trading volume of 4,139 shares, compared to its average volume of 4,219. The firm has a market cap of $154.45 million, a PE ratio of -1.84 and a beta of 1.10. Molecular Partners has a 52 week low of $3.36 and a 52 week high of $7.60. The business has a 50-day moving average price of $3.70 and a 200 day moving average price of $3.97.

Institutional Trading of Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. Suvretta Capital Management LLC raised its stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) by 455.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,221,494 shares of the company's stock after acquiring an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned about 5.50% of Molecular Partners worth $10,548,000 as of its most recent SEC filing. Institutional investors own 26.55% of the company's stock.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.